NCT06396208View on ClinicalTrials.gov

"Quick-starting of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition"

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions
Ultrasound Finding: Ovulation Inhibition, Ovarian ActivitiesCervical MucusSerum Hormonal Profile
Interventions
DRUG

Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2)

Completing a pack (28 pills) of Quadriphasic Estradiol valerate 1 - 3 mg/ Dienogest 2 - 3 mg (26/2), starting on day 7-9 of menstrual cycle

DRUG

Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7)

Completing a pack (28 pills) of Ethinylestradiol (EE) 20 mcg/Gestodene 75 mcg (21/7), starting on day 7-9 of menstrual cycle

Trial Locations (1)

10330

King Chulalongkorn Memorial Hospital, Bangkok

All Listed Sponsors
lead

Chulalongkorn University

OTHER

NCT06396208 - "Quick-starting of a Quadriphasic Contraceptive Pills, 1 - 3 mg Estradiol Valerate/ 2 - 3 mg Dienogest VS 20 mcg Ethinylestradiol/75 mcg Gestodene Focusing on Ovulation Inhibition" | Biotech Hunter | Biotech Hunter